Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.
A number of other research analysts have also weighed in on the company. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a report on Wednesday, January 3rd. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, December 29th. Goldman Sachs Group restated a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $26.00.
Atara Biotherapeutics (NASDAQ:ATRA) opened at $20.70 on Thursday. The stock has a market capitalization of $633.33, a P/E ratio of -5.97 and a beta of 1.27. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.05). equities analysts expect that Atara Biotherapeutics will post -4 earnings per share for the current fiscal year.
In related news, CEO Isaac E. Ciechanover sold 22,200 shares of Atara Biotherapeutics stock in a transaction on Friday, December 29th. The stock was sold at an average price of $18.29, for a total transaction of $406,038.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock in a transaction on Friday, December 29th. The stock was sold at an average price of $20.00, for a total value of $640,000.00. The disclosure for this sale can be found here. Insiders sold 121,788 shares of company stock worth $2,194,934 in the last 90 days. Corporate insiders own 16.20% of the company’s stock.
A number of institutional investors have recently modified their holdings of ATRA. Neuberger Berman Group LLC lifted its holdings in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after acquiring an additional 147,061 shares during the period. Artal Group S.A. lifted its holdings in Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after acquiring an additional 100,000 shares during the period. Perceptive Advisors LLC bought a new stake in Atara Biotherapeutics during the third quarter worth $581,000. Northern Trust Corp lifted its holdings in Atara Biotherapeutics by 12.0% during the second quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock worth $4,183,000 after acquiring an additional 32,065 shares during the period. Finally, Marshall Wace North America L.P. bought a new stake in Atara Biotherapeutics during the second quarter worth $425,000. Institutional investors and hedge funds own 85.61% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics (ATRA) Lifted to Buy at BidaskClub” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/atara-biotherapeutics-atra-lifted-to-buy-at-bidaskclub.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.